title: Predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients.
abstract: The Xeroderma pigmentosum complementation group G (XPG) rs2296147T>C polymorphism is suspected to associate with the clinical outcomes of cancer patients. However, the results are inconsistent. This meta-analysis aimed to evaluate the reliable predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients. A total of 11 eligible studies were enrolled in this meta-analysis. Our results indicated that the cancer patients with TT and CT genotypes were significantly associated with better respond rates when compared with the CC genotype (TT versus (vs.) CC: odds ratio (OR) = 2.05, 95% confidence intervals (CIs), 1.32-3.20, P = 0.002; TT+CT vs. CC: OR= 1.57, 95% CI, 1.14-2.17, P = 0.005). The TT genotype and/or T allele might be associated with higher survival time for cancer patients than the CC genotype and/or C allele. The cumulative meta-analyses showed an apparent beneficial objective response of TT genotype on cancer patients. In conclusion, this meta-analysis suggests that the XPG rs2296147T>C polymorphism is associated with the clinical outcomes of cancer patients. The XPG rs2296147T>C polymorphism might be a predictive factor of prognosis in cancers patients and contribute to individual treatment in the future.
authors: College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, People's Republic of China.
authors: Yuhan
authors: Y
authors: Wang
authors: College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, People's Republic of China.
authors: Yingying
authors: Y
authors: Han
authors: College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, People's Republic of China.
authors: Qiang
authors: Q
authors: Weng
authors: College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, People's Republic of China.
authors: Zhengrong
authors: Z
authors: Yuan
mesh_terms: D006801:Humans; D014408:Biomarkers, Tumor / Q000235:genetics; D016022:Case-Control Studies; D003131:Combined Modality Therapy; D020022:Genetic Predisposition to Disease; D005838:Genotype; D009369:Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; C497292:ERCC2 protein, human; D051759:Xeroderma Pigmentosum Group D Protein
keywords: XPG; cancer; clinical outcomes; meta-analysis; rs2296147